Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer - Wikidata - awgldk - TriplyDB

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

http://www.wikidata.org/entity/Q28241808

about

T cell receptor signalling in the control of regulatory T cell differentiation and function Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia PI3K isoform-selective inhibitors: next-generation targeted cancer therapies PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)Targeted Therapies in Adult B-Cell Malignancies Myeloid Cells as Targets for Therapy in Solid Tumors Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma Targeting cancer with kinase inhibitors Immune cell promotion of metastasis The role of regulatory T cells in cancer immunology First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors The phosphoinositide 3-kinase pathway and therapy resistance in cancer The biology behind PI3K inhibition in chronic lymphocytic leukaemia PI3K at the crossroads of tumor angiogenesis signaling pathways Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity.Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations.PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production.Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma Cellular and molecular immunology of lung cancer: therapeutic implications.Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes Initial treatment of CLL: integrating biology and functional status.Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway Disrupted PI3K p110δ Signaling Dysregulates Maternal Immune Cells and Increases Fetal Mortality In Mice.Sulindac, a non-steroidal anti-inflammatory drug, mediates breast cancer inhibition as an immune modulator.Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity.PI3Kδ and primary immunodeficiencies.Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.

P2860

Q26749508-3B56DDD8-DD72-4618-9C4C-A96D4A186B0B Q26779129-E155E7B5-4DF4-4100-B4AA-BCF2108C65E5 Q26781294-421C67E1-57C3-4B92-A5A7-14AA01445765 Q26782633-C66DB51D-AB43-40C1-A472-28EF0D33DA48 Q26783195-05FFD05C-B9AB-417E-B6FB-CD2B4A04CFE8 Q26801832-E6470206-BC32-4099-9925-79CBB05DF2A6 Q26801834-D85BEF62-DCE3-4F9C-B0F2-67AE07AE65B7 Q26823575-145CACDB-7D45-46F4-80C9-CC90DCEC1FA9 Q26865645-7A69F7F9-C931-461B-ACE3-9D9770D8A01D Q26865765-B333BFE1-CCBD-4BA0-809F-AB813BB2DEB5 Q26991724-7D4E0C11-EE4F-4DD2-BABB-1F3C53B36674 Q27006663-90192A0B-4231-4661-9A6F-AD3E988BB7C5 Q27853088-E799E848-C897-441D-9689-80A50F56FB3E Q27853225-71A05AD8-3049-4444-B37E-57BB87AE6FA4 Q28070264-63C50D31-A58A-47FE-A1E9-A94EEAC00A5B Q28082811-0076FB7C-48B8-4CFC-B92E-1D072410564E Q28083266-EE6EBB01-059F-4491-8749-55502437CCC7 Q28396795-A7BC58B9-A5E2-4DD1-8492-5AC5B42C8184 Q29248893-8E116303-0E77-4449-9907-2B67CA5FE055 Q33578997-AAC12240-80DC-4A98-BFB3-8C7B89A9F85E Q33779875-4F1F53D7-3511-4A98-A94B-6F0C8932F818 Q33785941-82C265E5-3E44-4A32-9220-B056118C356C Q34495723-2706CCAB-49B5-413D-8127-02F5B65B8D2C Q34512092-EB8D6881-512C-4350-BA15-FFF5A0D6D016 Q34979483-35DF02B7-6476-4F8F-B49A-98A0988AA7D3 Q35260766-F8DAD6B0-4C02-448E-A826-5023648FEDC3 Q35897436-342E6599-DA7F-4FEA-8E7D-0CA059EDDD1D Q36051184-DAC1AB76-E6E0-42B9-BEF6-A88CCC5947EB Q36130505-4B7D93E1-B58E-4E23-8551-5A3BA8C82B15 Q36169054-5F23994D-FB10-48C5-8B27-E803859715F3 Q36219647-E4650239-B8A4-499B-B9D4-2C1D644A19F9 Q36255950-5C141355-5BDC-4A3C-B992-CEA32775DC41 Q36426906-74CC522F-6AD6-44DA-8183-DE2E8F2BF584 Q36499777-E2C85407-3865-4BD2-B66F-FC79E67A2538 Q36601779-DCF3C1DE-DF7A-4BAA-A448-DDDB39A0A504 Q37079141-3E3A6A19-971C-4EF8-BA20-C83D9D01894E Q37097096-F2843FE2-7D7E-4491-9594-CCA2B7E6E6A3 Q37162527-117124C8-3E5F-4CA4-8642-2E574506F34B Q37623828-59EE31AD-3C27-4AEB-A2BF-535E8FDFE921 Q38521775-09982CE1-DC84-4C5B-967A-1553694D0452

P2860

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

http://www.wikidata.org/entity/Q28241808

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

@ast

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

@en

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

@nl

type

label

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

@ast

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

@en

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

@nl

prefLabel

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

@ast

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

@en

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

@nl

P1433

Q28241808-AD81605F-392F-4D89-ACA9-C37DA52C8656

P1476

Q28241808-2D1F6438-696B-4682-AE6B-39D220B81B79

P2093

Q28241808-1BDA5B21-2639-4F62-BF65-5FA466F6FEAB

Q28241808-26767BF5-9B58-40B0-A612-308254B4C212

Q28241808-52D0F945-0C58-4F99-B1FA-384118A85994

Q28241808-52D28065-F0E8-4038-B9C7-8CFFF68228B6

Q28241808-90616767-0B3C-43E1-B61D-91F5EF62522B

Q28241808-9974DE25-3ECE-4626-9E73-DD6DACDD0AC3

Q28241808-B405863B-8D1F-418B-A466-ABBE16F34544

Q28241808-BBF75E52-0EAE-4B0C-88B0-080B570F637D

Q28241808-EA55EDB9-E61F-4037-8820-CCB2F26DF028

P2507

Q28241808-90BFFE71-8181-4028-A4ED-D00AFD1706F0

P2860

Q28241808-0BF4C738-DC63-4D57-9BFD-7B546F086EA5

Q28241808-2B75093A-28B7-48AF-B0C9-B2A443E2B0FA

Q28241808-2D0C33BF-4E52-4B62-8497-FD2A45A3C5D4

Q28241808-2F37A0D7-2DCD-4F63-9A93-31E1E8AF82A2

Q28241808-493D07B5-8AFE-457B-A369-AB4E10BAC381

Q28241808-5024F069-964F-41E7-AC2A-64C3D9696806

Q28241808-55B1582F-F85E-411D-86F2-DC7030DBDE67

Q28241808-5B29301F-A4A3-4961-8492-FFE5BC793B86

Q28241808-62DED300-A2AF-4AEC-B9A0-DBEE6DE6D846

Q28241808-8412D6A9-590C-48A8-B386-43EEC00B16A6

P2888

Q28241808-CA427544-1791-4B1C-8664-E70C53865845

P304

Q28241808-A5E1595E-BBB0-4B3B-94D7-9F36FD540E41

P31

Q28241808-9D3A04E3-0BFE-49F2-BC57-19EE41B2508E

P3181

Q28241808-0E8C578B-17FF-4EA4-B2DF-FA29978C704E

P356

Q28241808-212BED54-7873-4070-ACB7-851A8B289F1D

P407

Q28241808-D7ED54FD-EEDF-4499-A3A8-6752B7261AE4

P433

Q28241808-774A5469-8B34-40CF-A332-DB33CCCC0DA5

P478

Q28241808-7FDE51C9-B9CF-4579-BE6C-9DD3E28F85C5

P50

Q28241808-29855511-9D0F-46D8-86EC-9B50C858556D

Q28241808-49166126-E7E8-45DD-81A0-D8FE9CB47CE3

Q28241808-83FFAA72-CF63-47F2-BDD4-A27564A9F7B4

Q28241808-8C387860-CA2C-4851-91EF-268B6EA7904C

Q28241808-C4250843-D8F3-4C83-B6C7-32F95C48A2AB

P577

Q28241808-942CD88A-0223-47FE-A8C7-1AAE25D96C2C

P5875

Q28241808-68BCFA05-1F7B-4223-9555-E01AD6842B53

P6179

Q28241808-3171B4F4-4D07-48D9-A1F2-F6E33602579A

P698

Q28241808-1503DFF0-BDEE-4425-918A-E11430DED441

P932

Q28241808-B9E9F1E9-23B8-4E36-933B-C17D176A49FA

P3181

P356

P1433

P1476

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

@en

P2093

Bart Vanhaesebroeck

http://www.w3.org/2001/XMLSchema#string

Dalya R Soond

http://www.w3.org/2001/XMLSchema#string

Heather Maecker

http://www.w3.org/2001/XMLSchema#string

Hicham Bouabe

http://www.w3.org/2001/XMLSchema#string

Khaled Ali

http://www.w3.org/2001/XMLSchema#string

Lori Friedman

http://www.w3.org/2001/XMLSchema#string

Thorsten Hagemann

http://www.w3.org/2001/XMLSchema#string

Timothy Hancox

http://www.w3.org/2001/XMLSchema#string

Wayne Pearce

http://www.w3.org/2001/XMLSchema#string

P2507

Corrigendum: Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

P2860

P110delta, a novel phosphoinositide 3-kinase in leukocytes

Potent and highly selective benzimidazole inhibitors of PI3-kinase delta

Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice

Signaling by the phosphoinositide 3-kinase family in immune cells

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Coordinated regulation of myeloid cells by tumours

The PI3K p110δ regulates expression of CD38 on regulatory T cells

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

PI3K and cancer: lessons, challenges and opportunities

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

P2888

P304

407-411

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1752059

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE13444

http://www.w3.org/2001/XMLSchema#string

P407

P433

7505

http://www.w3.org/2001/XMLSchema#string

P478

510

http://www.w3.org/2001/XMLSchema#string

P50

Klaus Okkenhaug

Roberto Piñeiro

Cheryl Scudamore

P577

2014-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263014296

http://www.w3.org/2001/XMLSchema#string

P6179

1027340229

http://www.w3.org/2001/XMLSchema#string

P698

24919154

http://www.w3.org/2001/XMLSchema#string

P932

4501086

http://www.w3.org/2001/XMLSchema#string